Building capacity for the assessment of HIV drug resistance: Experiences from the pharmaccess African studies to evaluate resistance network

Clinical Infectious Diseases

Volumn 54, Issue SUPPL. 4, 2012, Pages

  Hamers, Raph L ^a   Straatsma, Elske ^a   Kityo, Cissy ^c   Wallis, Carole L ^d   Stevens, Wendy S ^d   Sigaloff, Kim C E ^a   Siwale, Margaret ^f   Conradie, Francesca ^d   Botes, Mariette E ^e   Mandaliya, Kishor ^g   Wellington, Maureen ^h   Osibogun, Akin ⁱ   Van Vugt, Michle ^a,b   De Wit, Tobias F Rinke ^a  

^a PharmAccess Foundation   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e Muelmed Hospital   (South Africa)

^f Lusaka Trust Hospital   (Zambia)

^g Department of Obstetrics and Gynaecology   (Kenya)

^h Newlands Clinic   (Zimbabwe)

ⁱ LAGOS UNIVERSITY TEACHING HOSPITAL   (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

AFRICA; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL PROTOCOL; FINANCIAL MANAGEMENT; FUNDING; GOOD LABORATORY PRACTICE; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INTERNET; LABORATORY TEST; MICROCOMPUTER; MOLECULAR DIAGNOSIS; OBSERVATIONAL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; PUBLIC HEALTH; QUALITY CONTROL; SEQUENCE ANALYSIS; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

AFRICA; ANTI-HIV AGENTS; CAPACITY BUILDING; DEVELOPING COUNTRIES; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HUMANS; POPULATION SURVEILLANCE; PUBLIC HEALTH ADMINISTRATION; WORLD HEALTH ORGANIZATION;

EID: 84860360727     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir995     Document Type: Article

References (15)

1. World Health Organization. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2010. Available at: http://www.who.int/hiv/pub/tuapr-2010-en.pdf.Accessed 1 June 2011.
2. Hamers RL, Derdelinckx I, Van Vugt M, Stevens W, Rinke de Wit TF, Schuurman R. The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa. Antivir Ther 2008; 13:625-39.
3. Gupta RK, Hill A, Sawyer AW, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 2009; 9:409-17.
4. Hamers RL, Wallis CL, Kityo C, Siwale M, Mandaliya K, Conradie F, et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. The Lancet Infectious Diseases 2011; 11:750-9.
5. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther 2008; 13(Suppl 2):1-13. (Pubitemid 352019085)
6. Hamers RL, Oyomopito R, Kityo C, et al. Cohort Profile: the PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring Studies to Evaluate Resistance-HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. Int J Epidemiol. 2011; [Epub ahead of print].
7. Hamers RL, Schuurman R, Sigaloff KCE, et al. Effect of pretreatment HIV-1 drug-resistance on immunological, virological and drug-resistance outcomes of first-line antiretroviral treatment: multicentre cohort in six African countries. The Lancet Infectious Diseases 2011.
8. Sigaloff KCE, Hamers RL, Wallis CL, et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr 2011; 58:23-31.
9. Sigaloff KCE, Mandaliya K, Hamers RL, et al. High prevalence of transmitted antiretroviral drug resistance among newlyHIV-1 diagnosed adults in Mombasa, Kenya. Aids Research and Human Retroviruses 2011; [Epub ahead of print].
10. Ndembi N, Hamers R, Sigaloff K, et al. Transmitted antiretroviral drug resistance spreading in Kampala? AIDS 2011; 25:905-10.
11. Jordan MR, Bennett DE, Bertagnolio S, Gilks CF, Sutherland D. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther 2008; 13(Suppl 2):15-23. (Pubitemid 352019086)
12. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 2008; 13(Suppl 2):25-36. (Pubitemid 352019087)
13. Land S, Cunningham P, Zhou J, et al. TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories. J Virol Methods 2009; 159:185-93.
14. Bertagnolio S, Derdelinckx I, Parker M, et al. World Health Organization/HIVResNet drug resistance laboratory strategy. Antivir Ther 2008; 13(Suppl 2):49-57. (Pubitemid 352019089)
15. Hamers RL, Smit PW, Stevens W, Schuurman R, Rinke de Wit TF. Dried fluid spots for HIV type-1 viral load and resistance genotyping: a systematic review. Antivir Ther 2009; 14:619-29.